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Luminal and intracellular cGMP inhibit the mTAL reabsorptive
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Luminal and intracellular cGMP inhibit the mTAL reabsorptive ca-
pacity through different pathways. Since, in the presence of ANF,
urinary cGMP was shown to be of glomerular origin, a possible
paracrine effect of luminal cGMP on the medullary thick ascending limb
(mTAL) function was investigated. Net chloride reabsorption (J) was
determined on isolated microperfused tubules from mouse kidney.
Addition of lO M cGMP to the lumen significantly decreased J1 by
46.5 4.6%. A concentration-dependent decrease of the transepithelial
voltage was observed, with a lO8 M threshold. Added to the bath, ANF
(1O- M) as well as urodilatin (6 x 10 M) decreased Ja by 29.8 3.9%
and 36.9 5.1%, respectively, an effect reproduced by 8-bromo cGMP
and associated with a significant increase in tubular cGMP content. The
inhibitory effect of ANF was similar whether or not cGMP was present
in the lumen. Furthermore, increasing intracellular cGMP content by
8-bromo cGMP did not prevent a further effect of luminal cGMP.
Finally, H-8, which blocked the effect of ANF, urodilatin, and 8-bromo
cGMP, failed to abolish the luminal cGMP-induced decrease of J1,
suggesting that this effect did not require a cGMP-dependent protein
kinase activation. It is concluded that luminal cGMP inhibits the
reabsorptive function of the mTAL through a pathway different from
the intracellular cGMP production.
It is well-established that cyclic GMP (cGMP) mediates the
action of atrial natriuretic factor (ANF) on its target cells [1].
From the glomeruli, moreover, cGMP was shown to be ex-
truded out of the epithelial cell, preferentially through the apical
side [2], which accounted for the presence of the nucleotide in
the proximal tubular fluid and urine [31. Therefore, the question
arises of whether there is a paracrine effect of cGMP from
glomerular origin on the tubular function.
On the whole kidney, a recent study suggested that cGMP,
the glomerular secretion of which was increased by ANF, might
be involved in the natriuretic effect of the hormone [4]. Since
ANF is known to inhibit sodium reabsorption in the medullary
collecting tubule [1], the cGMP effect was supposed to take
place in this segment. In alignment with that study a cGMP-
gated cationic channel was recently reported on the apical
membrane of inner medullary collecting tubule cells [5]. At
variance with the collecting tubule, no information is available
yet on a possible modulation of the reabsorptive function of the
medullary thick ascending limb (mTAL) by luminal cGMP.
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Regarding a possible effect of ANF in the mTAL, the results
are still conflicting. Indeed, on the one hand no binding of ANF
was in evidence [61, no [7] or few [8] ANF-stimulated cGMP
production was detected, and no effect of the hormone on
sodium reabsorption was observed either in the rat in vivo [9] or
in the rabbit in vitro [10]. On the other hand, mRNA coding for
a guanylate cyclase-coupled ANF receptor has been detected
[11], and, very recently ANF was shown to inhibit the anti-
diuretic hormone-stimulated chloride reabsorption in this seg-
ment [12].
The present study was thus undertaken to investigate the
influence of luminal cGMP on the reabsorptive capacity of the
mTAL by determining the net chloride reabsorption (J1) and
the transepithelial voltage (Vs) in isolated microperfused tu-
bules. Moreover, since the kidney was reported to secrete a
natriuretic peptide—urodilatin (URO)—structurally related to
ANF [13], a possible effect of ANF and URO on J, was
investigated as well.
The results indicated that luminal cGMP decreased J1 simi-
larly to basolateral ANF and URO, but, at variance with the
natriuretic hormones, did not induce such an effect through
protein kinase activation or increased intracellular cGMP con-
centration.
Methods
Microperfusion experiments
mTALs were microperfused in vitro following the technique
first described by Burg et al [14]. Male Swiss white mice, 18 to
20 g body weight, were killed by cervical dislocation and
exsanguinated. Coronal slices were then cut from both kidneys
and were immediately immersed in a cold perfusing solution
(see composition detailed below) added to 0.4% bovine serum
albumin. mTALs (length = 571 34 mm, N = 49) were
harvested from the inner stripe of the outer medulla. The
segments were then transferred to a Lucite chamber in which
the bath, thermostatically maintained at 36 0.1°C, was
continuously flowing at about 5 mI/mm. When the tubular fluid
was collected, the tubules were perfused in the control period
(see below) at a rate of 5.4 0.3 nI/mm, not significantly
different from that flowing during the experimental period
(5.5 0.3 nI/mm). When Vt was recorded, the tubular fluid was
not collected and the tubular flow rate was high enough to
assume that no dilution potential was generated.
Each perfused tubule was allowed to equilibrate during
one-half hour. After equilibration, a 30-minute control period
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was followed by one or two 30-minute experimental periods,
during which the luminal fluid was collected every 10 minutes.
Between each period, 10 minutes were allowed for equilibra-
tion. When cOMP was present on the luminal side, the luminal
fluid was changed by hand, through a syringue filled with 2 ml
solution (about 10-fold the volume of the perfusing system),
while by microscopic observation it was checked that the tubule
was not submitted to important pressure variations. It was
verified that this maneuver did not significantly modify J,
within a time frame or maneuver the control tubules (see
Results).
The composition of the perfusing solution was as follows (in
mM): NaCI 147, MgCI2 2, CaCI2 1, KCI 2, urea 10, N-2-
hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) 10.
The composition of the bathing solution was similar, except for
a lower NaCI concentration, 142 m, because of the addition of
glucose (5 mM), and Na acetate (5 mM). All the solutions were
adjusted to 300 mOsm/kg H20 with urea, and to pH 7.39 to 7.42.
Vt was recorded (Keithley Instruments, Cleveland, Ohio,
USA) between two calomel electrodes connected to the bath
and perfusate by 5% agar bridges in 0.9% NaCI. The volume of
the collected samples was measured with a calibrated constric-
tion pipette, and the flow rate of the perfusate (V) was calcu-
lated assuming that water reabsorption was negligible in the
mTAL [12]. In the collected fluid and perfusate, chloride
concentration (C and C,,, respectively) was determined by
microelectrometric titration [15]. The net chloride reabsorption
was calculated as = (C — C,,) >< V. Since it was reported
that, in the mouse mTAL, the chloride reabsorption is not
proportional to the tubular length when the chloride concentra-
tion decreases [16], the net fluxes were not monitored by this
parameter.
Unless otherwise mentioned, the steady state data from each
period were pooled and considered as one point. Values were
expressed as means SE. Statistical significance was evaluated
within each series by the paired Student's i-test, and between
series by the one-way analysis of variance followed by the
Fisher's least significant difference test.
cGMP content
cGMP content was determined by radioimmunoassay in
single mTAL tubular segments, following a procedure first
described by Chabardes et al [7]. Male Swiss white mice were
anesthetized with sodium pentobarbital (0.1 mg/b g body wt).
The left kidney was perfused in situ via the abdominal aorta
with 5 ml of incubation solution containing (in mM): NaCl 120,
KCI 5, CaC12 I, MgSO4 1, NaH2PO4 4, NaHCO3 4, glucose 5,
lactate 10, pyruvate 1, arginine 0.8, and HEPES 20. Dextran
40,000 (0.3% wt/vol), collagenase (151 U/mg) 0.3% wt/vol, and
bovine serum albumin 0.1% wt/vol were added. The left kidney
was removed and thin pyramids were then cut out along the
corticopapillary axis of the kidney, and were incubated for 15
minutes at 35°C in the incubation solution containing 0.1%
collagenase. mTALs were microdissected from the inner stripe
of the outer medulla. The length of the tubules was determined
with an ocular micrometer. A pool of tubular segments (about
15 to 20 mm for each measure) was transferred into a tube
containing 10 Mi incubation solution added with 1O M 3-isobu-
tyl-1-methylxanthine (IBMX). Each sample was preincubated
15 minutes at 35°C, and then incubated 10 minutes at 35°C after
Fig. 1. Evolution with time of net chloride reabsorption (Jci) in the
mTAL. J,1 was expressed as percentage of the first control value (C,).
In time and maneuver control tubules (0), J,, in C, was 43.8 13.1
pmol/min (N = 4); at the time indicated by the arrow, the luminal
solution was changed without modification of its composition. In
tubules receiving luminal cGMP (*), c, in C, was 56.9 11.6 pmol/min(N = 8); at the time indicated by the arrow, 10-6 M cOMP was
administered in the luminal solution. *Significantly different (P C 0.01)
from the time and maneuver control tubules.
addition of the required hormones (10 jil). The reaction was
stopped with 200 ,td of 90% (vol/vol) ethanol and 10% (vol/vol)
formic acid, at 4°C. After evaporation, acetate buffer was added
and cGMP was determined by radioimmunoassay, after acety-
lation. The limit of detection was 3 femtomoles of cGMP per
tube.
Materials
Rat atriopeptine III was purchased from Calbiochem (La
Jolla, California, USA), Urodilatin from Peninsula Laboratories
(Belmont, California, USA), N-[2-(methylamino)-ethyl]-5-iso-
quinoline-sulfonamide (H-8) from Research Biochemicals In-
corporated (Natick, Massachusetts, USA), collagenase CLS II
from Worthington Biochemical Corporation (Freehold, New
Jersey, USA), and labeled I'25cGMP from Amersham. All other
compounds were purchased from Sigma Chemical Corporation
(St. Louis, Missouri, USA).
Results
Effect of luininal cGMP on the InTAL reabsorptive function
(Jo and V,)
When perfused on the luminal side (Fig. 1, left columns of
Fig. 2), cGMP 10_6 M significantly (P < 0.01) decreased J0
from 55.6 12.1 to 30.6 7.4 pmol/min, The changing of the
luminal solution without alteration of its composition in time
and maneuver of control tubules did not significantly decrease
JO (—0.9 9.8% inhibition, not different from zero; Fig. I). The
polarity of the inhibitory effect of cGMP on J0 was checked by
adding 10 M cOMP to the bath (Fig. 2): In this condition, J,
was decreased by 12.5 2.8%, a value significantly lower than
that observed in the presence of luminal cGMP (46.5 4.6, P C
0.001).
Since J, is highly correlated to V in the mTAL [17], the
effect of increasing concentrations of luminal cGMP was tested
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Fig. 2. Effect of cGMP on net chloride reabsorption (Jr,) in the mTAL.
I0 M cGMP was added either in the lumen [cGMP(l)} or in the bath
[cGMP(b)]. C: control period. *significantly different (P < 0.01) from
control.
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Fig. 3. Effect of increasing concentrations of luminal cGMP on the
transepithelial voltage (V,). The curve was drawn by hand. Except
when no effect on Vt was observed, one concentration was tested on
one tubule. (N) is the number of determinations. Mean control value:
4.3 0.5 mV (N = 13). For 108 M, Vt was significantly different from
100% (P < 0.01).
on this latter parameter. A concentration-dependent decrease
of Vt was observed with a threshold of significance at 10—8 M
(P < 0.01, Fig. 3).
Effect of basolateral ANF and URO on J, in the mTAL
In isolated mTALs, ANF as well as URO induced a signifi-
cant increase in cGMP content, lower for URO than for ANF
(Table 1). Both ANF and URO (10 M and 6 x 10—8 M in the
bath, respectively) decreased J1 to the same extent from 73.7
18.5 to 53.4 14.5 pmol/min and from 53.2 12.5 to 35.0 9.9
pmol/min, respectively (P < 0.01, Fig. 4). Since ANF and URO
were reported to bind a common receptor [1 8], the reversibility
of the inhibitory effect of these hormones on J1 was tested only
for URO. After removal of the hormone, increased to 41.7
10.3 pmol/min, which represented 78.2 3.2% of the control
value and differed (P < 0.05) from the value in the presence of
the hormone.
The effect of ANF and URO on Jc1 were mimicked by l0— M
Basal
Stimulated
cGMP content
fmol. 10 min' mm'
ANF URO
0.49 0.34 0.16 0.06
(9) (8)
16.0 6.9a 0.77 0.3o
(8) (5)
Values are means SE. (N) is the number of experimental points.
About 20 mm tubular segment were harvested for one point.
Significantly different from basal, P < 0.05
E
Fig. 4. Effect of ANF and urodilatin on net chloride reabsorption (Jr,)
in the mTAL. Abbreviations are: C, control period; E, experimental
period during which either I07 M ANF (0, N = 5) or 6 x l0_8 M
urodilatin (, N = 5) was present in the bath; R, recovery period.
8-bromo cGMP in the bath since J1 was significantly (P < 0.01)
decreased from 67.8 10.0 in the control period to 47.7 8.6
pmol/min (N = 9) in the presence of this agent (Fig. 5, left and
middle columns).
Additive effects of luminal cGMP and intracellular cGMP on
Jc, in the mTAL
In the presence of 10 M luminal cGMP, iO M ANF in the
bath further decreased J1 by 20.4 2.0 prnol/min, a decrease
not different from that obtained in the absence of luminal cGMP
(20.3 4.4 pmol/min, Table 2). Moreover, a further action of
l0 M luminal cGMP was observed in the presence of iO M
8-bromo cGMP in the bath, while this latter agent prevented a
further effect of iO M basolateral ANF (Fig. 5, middle and
right columns).
Effect of H-8 on the inhibitory action of cGMP on J1
To investigate whether luminal cGMP required activation of
cGMP-dependent protein kinase to inhibit Jci, experiments
have been performed in the presence of H-8, a protein kinase
inhibitor more specific for the cGMP-dependent than for the
Table 1. Effect of ANF and urodilatin (URO) on cGMP content in
isolated mTAL
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Fig. 5. Effect of 8-bromo cGMP in the bath on the inhibition by luminal
cGMP and basal ANF of net chloride reabsorption (Jr,) in the mTAL.
After a control period (C), 8-bromo cGMP l0 Sf (8 BrcG) was added
to the bath. Then either cGMP 10—6 M was perfused on the luminal side
(N = 5) or ANF io— M was added in the bath (N = 4). *, §significantly
different (P < 0.05) from control (*) or from the preceding period ($).
.
V
nI/mm
Cl
mM
J0
pmol/min
Without cGMP (5)
Control 6.5 0.3 11.5 3.0 73.7 18.5
ANF(b) 6.5 0.4 9.1 3,1b 53•4 5b
With cGMP (5)
Control 6.8 0.6 7.2 0.9 49.0 7,0
ANF(b) 5.9 0.6a 4.7 0.8 28.6 5.8w
Values are means SE. ANF l0— 54 was present in the bath
[ANF(b)] during the experimental period. When added, cGMP 10_6 Sf
was present in the lumen throughout the experiment. Abbreviations
are: V, tubular flow rate; Cl, chloride concentration difference be-
tween the perfused and the collected fluid; J1, net chloride reabsorp-
tion; (N), number of tubules.
Significantly different from control: a P < 0.05; b P < 0.01; P <
0.001
cAMP-dependent kinase. H-8, 10_6 M in the bath, did not
significantly modify J (48.9 10.6 vs. 56.4 11.5 pmol/min,
NS, N = 7). When present in the bath from the control period,
H-8 failed to abolish the inhibitory effect of luminal cGMP on
Jc1 (Table 3). In the same conditions, however, H-8 completely
blocked the effect of intracellular cGMP increased by either
ANF, URO, or 8-bromo cGMP in the bath (Table 3).
Discussion
The results reported in the present work showed that luminal
cGMP inhibited the reabsorptive function of the mTAL. Simi-
larly, basolateral ANF and URO decreased J1 in the absence of
any hormonal stimulation of the cyclic AMP production. More-
over, the luminal cOMP effect on jc did not require activation
of cGMP-dependent protein kinase, and was induced through a
pathway different from that involving an intracellular cGMP
production. This study strongly argues for a paracrine tubular
action of cGMP.
V
nI/mimi
Cl
mM
Jci
prnol/min
H-8 4.4 0.2 11.1 1.0 48.2 5.7
11-8 -- cGMP(l) 5.0 0.4 4.8 1.3 25.4 3,7'
H-8 6.7 1.0 8.6 1.9 63.0 18.2
H-8 + cGMP(i) 6.6 1.1 8.3 1.0 57.2 14.2
Values are means SE. cGMP(l): 106 M cGMP was present in the
lumen during the experimental period (N = 4). cGMP(i): either ANF
iO M (N 2), URO 6 x 10 M (N = 2),or 8-bromo cGMP l0- M (N
= 1) was added in the bath during the experimental period. H-8 lO_6 at
was present in the bath throughout the experiment. Abbreviations are in
Table 2.
Significantly different from the control value: a p < 0.05; b p < 0.01
Effect of luminal cGMP on the mTAL reabsorptive function
The data reported here clearly indicate that cGMP, present
on the luminal side, decreased net chloride reabsorption and Vt.
There is evidence that luminal cGMP and intracellular cGMP
acted through different pathways: (i) luminal cGMP did not
prevent a further effect of ANF; (ii) the effect of lO_6 M cGMP
was still observed after addition of iO M 8-bromo cGMP in the
bath, a concentration that increased intracellular cGMP content
sufficiently to prevent a further effect of ANF; and (iii) inhibit-
ing the cGMP-dependent protein kinase did not abolish the
effect of luminal cGMP, contrary to what was observed with
ANF, URO and 8-bromo cGMP. Since H-8 can inhibit the
cAMP-dependent protein kinase as well, although with a lower
sensitivity than the cGMP-dependent one, a possible activation
by intracellular cGMP of the cAMP-dependent protein kinase
may be questioned. However, the fact that cAMP stimulates J,1
in the mTAL [17] totally excluded this hypothesis. The present
results raise the following hypotheses: (i) cGMP remained
outside the cell or (ii) cGMP entered the cell and then was
incorporated in a cGMP pool different from that resulting from
a basolateral guanylate-cyclase stimulation. That the luminal
cGMP effect did not require activation of cGMP-dependent
protein kinase suggested that the luminally applied nucleotide
acted directly on one or several transporters in the apical
membrane, namely the Na-K-2C1 cotransport and/or the potas-
sium conductance. Such a direct inhibitory effect of cGMP was
recently reported on patched channels from cultured medullary
collecting tubule cells, an amiloride-sensitive sodium channel
[191, and a cationic channel similar to the cGMP-gated rod
photoreceptor [51.
Inhibitory effect of ANF and URO on J,
The results presented here indicate that ANF as well as URO
decreased net chloride reabsorption in the mTAL. This repre-
sents the first indication of an effect of URO on the tubular
reabsorptive function, although this was observed at a high
concentration of the hormone. The effect of URO on J1
reported here was to the same extent as that observed with
ANF. A similar natriuretic effect for both hormones has been
reported on the whole kidney [201. Contrary to a similar
inhibitory effect on J1, the increase of cGMP content was more
important with ANF than with URO. Such a difference of the
effect between ANF and URO on cGMP content was not
0
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Table 3. Effect of luminal and intracellular cGMP on chloride
reabsorption by the mTAL, in the presence of H-8
C 8BrcG 8BicG C 8BrcG 8BrcG
.GMP(I) +ANF(b)
Table 2. Effect of basolateral ANF on J,, in the mTAL in the
presence or in the absence of luminal cGMP
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observed in the medullary collecting duct [21]. This can be
explained by: (i) the twofold lower concentration used for URO
than for ANF, and (ii) a higher sensitivity to the hormones of
the chloride transport than of cGMP production, allowing that
the maximal effect was reached with both hormones for the
former while it was not for the latter.
The inhibitory effect of ANF and URO on J1 presented here
was observed in the absence of antidiuretic hormone. Such an
effect was in accordance with the absence of a decrease by
ANF of the antidiuretic hormone-stimulated cAMP production
in the mTAL [8]. These results are at variance with those
obtained by Nonoguchi, Tomita and Marumo [121 in the mTAL
in the rat. These authors, indeed, reported a significant de-
crease by ANF of J1 in the presence but not in the absence of
antidiuretic hormone. This discrepancy may have resulted not
from species differences, but rather from the absence of stabil-
ity with time of J1 observed by Nonoguchi et al [12] but not
observed in the present work. In the former work, indeed, the
effect of ANF on J1 in the absence of antidiuretic hormone may
have been masked by the spontaneous decrease of 40% of J1
with time.
Physiological relevance of the luminal cGMP inhibitory effect
on mTAL reabsorptive capacity
The luminal cGMP concentration reached in the mTAL in
vivo can be derived from its concentration in the proximal
tubule [3] and the water reabsorption upstream of the distal
tubule. cGMP concentration can reach the 10—8 M range in
basal conditions, and the l0 M range after ANF administra-
tion. The threshold of the luminal cGMP effect on Vt observed
in the present work is 10_8 M. In an in vivo study in the rat,
Norling, Vaughan and Chevalier [4] observed a parallel evolu-
tion between the cGMP glomerular secretion and the natriuretic
effect of ANF, suggesting a tubular effect of this nucleotide. A
paracrine effect of another nucleotide on the tubular function
was recently reported, since luminal cyclic AMP, the proximal
tubular secretion of which was increased by the parathyroid
hormone, accounted for about 30% of the inhibitory effect of
the hormone on phosphate reabsorption by this segment [22].
In summary, the present work showed that luminal cGMP
inhibited the reabsorptive function of the mTAL. This strongly
suggests that ANF modulates mTAL reabsorption by a dual
mechanism of action: the first one involving a direct basolateral
effect on the mTAL resulting in an increase of intracellular
cGMP content, and the second one through a paracrine luminal
action of the cGMP from a glomerular origin.
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